2007 PERFORMANCE

Reported performance

Infection sales grew by 96% to $1,715 million from $875 million in 2006, driven by the inclusion of seven months of Synagis and FluMist sales and Merrem sales increases of 28%.

Underlying performance

After excluding the effects of exchange, infection sales grew by 89%. Underlying growth of 20% from Merrem, with sales of $773 million, and the inclusion of Synagis and FluMist were the principal drivers of this growth. Sales of Synagis totalled $618 million for the period since the acquisition of MedImmune, with $480 million arising in the fourth quarter. Synagis sales are highly seasonal, with the majority of sales recorded in the fourth and first quarters. US sales were $391 million; sales outside the US were $89 million. There are no corresponding sales recorded in the prior year period; on a pro-forma basis Synagis sales are 5% ahead of the fourth quarter last year.

Sales of FluMist were $53 million for the full year, all of which were recorded in the fourth quarter. As with Synagis, there are no corresponding sales in the prior year period; on a pro-forma basis FluMist sales for the 2007/2008 influenza season to date are 56% ahead of the equivalent point in respect of the 2006/2007 season.

Sales of Merrem increased by 20% to $773 million, with strong growth in the US (sales up 32% to $149 million) and Western Europe (sales up 20% to $307 million).

2006 PERFORMANCE

Reported performance

Infection and other sales rose by 4% from $839 million in 2005 to $875 million in 2006, as sales of Merrem grew by 20%.

Underlying performance

Excluding effects of exchange, underlying sales in Infection increased by 4%. Merrem sales grew by 19% to reach $604 million, primarily driven by increased performance in the US and Europe.